Form 4: Evoke Pharma Director, Vickie S. Reed, Reports Stock Option Grant

Director Vickie S. Reed of Evoke Pharma, Inc. reports the acquisition of stock options.

Summary

• On May 22, 2024, Vickie S. Reed, a director of Evoke Pharma, Inc., reported the acquisition of stock options.
• The stock option grants the right to buy 15,000 shares of common stock at an exercise price of $0.451 per share.
• The options vest on the one-year anniversary of the grant date, contingent upon continued service to the issuer.
• Following the transaction, Ms. Reed directly owns 15,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to a director, which is a common practice.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of one year is typical for such grants, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like Ardelyx or Synergy Pharmaceuticals also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.

Key Dates

Keywords

stock options, Form 4, Evoke Pharma, director, beneficial ownership, securities